ClinicalTrials.gg
WithdrawnNCT05983354Updated Oct 5, 2026

Oral Medications for the Management of Acute Migraine Headache in the Emergency Department

An interventional study of Oral metoclopramide and ibuprofen and Intravenous metoclopramide and ketorolac in Acute Migraine Headache, sponsored by Health Sciences North Research Institute. Withdrawn. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionMigraine DisordersRegistry: EmergenciesReclassifiedWhy we changed it
Registry
Emergencies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Migraine Disorders
Why
  1. Emergencies describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Migraine Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Health Sciences North Research Institute · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
The project proved not feasible to launch at Health Sciences North.
Updated Oct 5, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing metoclopramide in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Metoclopramide · Migraine Disorders.

Enrollment
8th of 10
0 · median 100
Started
2023
the only one that year
No phase
2 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Health Sciences North Research Institute

Among the 10 studies testing metoclopramide in Migraine Disorders, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 2 with no phase, and was the 10th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 10 studies testing metoclopramide in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →

About metoclopramide

Metoclopramide: first FDA approval 1979 (REGLAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing metoclopramide in Migraine Disorders as a file.
02

Study summary

The goal of this pilot randomized control trial is to assess the feasibility of our patient recruitment and data collection strategy ahead of a full scale RCT investigating the efficacy of oral v. parenteral medications in the management of acute migraine headaches in the emergency department. Patients will be randomly assigned to receive either (A) standard medical therapy for the treatment of acute migraine headache (metoclopramide and ketorolac IV) and oral placebo or (B) oral metoclopramide and ibuprofen with normal saline IV. Primary outcome measures are recruitment rate and improvement in pain score at 60 minutes from medication administration.

Read the detailed description

Objectives

The planned study is a pilot study designed to assess the feasibility of our recruitment and data collection strategy. The primary feasibility outcome will be recruitment rate, which is defined as the proportion of eligible patients approached who are successfully recruited over the proposed 6-month pilot study period. Our secondary feasibility outcomes are (a) proportion of eligible patients approached and (b) rate of attrition during the study period.

Our preliminary primary outcome will be improvement in pain from baseline to 60 minutes after medication administration using the visual analogue scale (Bijur et al. 2008). Preliminary secondary outcomes will include headache relief and freedom from headache at 2 h, the need for rescue medication, ED length of stay and return to ED within 24h of discharge. The frequency of adverse effects, including gastrointestinal upset, patient-reported restlessness or dystonic reaction and fatigue, will be assessed.

Design

In this parallel, noninferiority, double-blind randomised control pilot study, eligible patients presenting to the emergency department with a chief complaint of headache will be randomly assigned with an allocation ratio of 1:1 to receive one of 2 treatments: intravenous ketorolac (10 mg) and metoclopramide (10 mg) v. oral ibuprofen (400 mg) and metoclopramide (10 mg). Dosing was selected to reflect the lowest effective doses recommended for emergency department management of migraine headaches (Friedman et al. 2011, Motov et al. 2017). The study will last 6 months at which time it will stop.

Study population

Patients between the ages of 18 and 64 presenting to the ED with a chief complaint of headache will be eligible to participate in the study. Exclusion criteria include vomiting or inability to tolerate oral medications at the time of medication administration, focal neurologic symptoms, head trauma within 14 days, history of renal disease, contraindication to NSAIDs including pregnancy or concurrent use of blood thinners, hypersensitivity reaction to any of the study medications, or >15 headache days per month.

Study procedures

Treatment will be assigned using a random number generator. Contents of treatment, which will be identical in appearance, will be known only to the research pharmacist and this information will be stored remotely from the ED. Administering nurses and treating physicians will be blind to the treatment group, as will patients and research assistants collecting outcome data.

Data collection

Data will be collected using patient interviews immediately prior to medication administration and repeated at 1 and 2 hours after medication administration. A chart review will then be conducted to check for return visits within 24 h of ED discharge.

Enrolment:

Based on sample size calculations, 55 patients will be enrolled.

Statistical procedures:

Primary and secondary feasibility outcomes will be reported as the proportion of patients approached who were recruited, proportion of eligible patients approached and the proportion who withdrew consent during the study period +/- 95% CI.

03

Conditions studied

  • Acute Migraine Headache

Browse trials for

Keywords

  • emergency department
  • migraine
  • metoclopramide
04

In context

Migraine Disorders Reclassified

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Lead sponsor

Health Sciences North Research Institute is the lead sponsor of 10 studies on the registry; none are open to participants now.

Compared within Migraine Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Emergencies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Presentation to emergency department with headache

Exclusion criteria

Exclusion Criteria:

  • Vomiting or unable to tolerate PO at tie of med admin
  • Focal neurologic symptoms
  • Head trauma within 14d
  • Pregnancy
  • Concurrent use of blood thinners
  • reaction to any of the study medications
  • >14 HA days per month
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Oral medications

    10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml NS administered over 15 minutes.

    Drug: Oral metoclopramide and ibuprofen

  • Active comparator
    IV medications

    2 x placebo tablets, 10 mg metoclopramide in 50 cc NS and 10 mg ketorolac in 50 ml NS administered over 15 min.

    Drug: Intravenous metoclopramide and ketorolac

Interventions

07

What researchers measure

Primary outcomes

  1. Recruitment rate

    Proportion of eligible patients presenting to ED who are successfully recruited

    Time frame: 6 months

  2. Pain relief

    Change in visual analogue scale (0-10 where 0 is no pain and 10 is maximal pain) from baseline to 60 minutes after medication administration

    Time frame: 60 minutes

Secondary outcomes

  1. Proportion of eligible patients approached

    Proportion of all eligible patients who were approached by research assistants

    Time frame: 6 months

  2. Rate of attrition during the study period

    Number of patients recruited to study who ended participation during study period

    Time frame: 24 hours

  3. Pain relief at 2 hours

    Change in visual analogue scale from baseline to 120 minutes after medication administration

    Time frame: 120 minutes

  4. Freedom from headache

    Patients who report complete resolution of headache at 60 minutes from medication administration

    Time frame: 60 minutes

  5. Need for rescue medication

    Additional medications administered by treating physician after 60 minutes

    Time frame: 24 h

  6. Emergency department length of stay

    Time from initial physician assessment to discharge

    Time frame: 24 hours

  7. Return to emergency department

    Patients who were registered again to the ED within 24 hours of discharge

    Time frame: 24 hours

  8. Adverse reactions

    Any adverse reaction reported during the study period

    Time frame: 24 hours

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Azzopardi TD, Brooks NA. Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine. Ann Pharmacother. 2008 Mar;42(3):397-402. doi: 10.1345/aph.1K481. Epub 2008 Feb 19. PubMed 18285561 ↗
  • Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 2001 Dec;8(12):1153-7. doi: 10.1111/j.1553-2712.2001.tb01132.x. PubMed 11733293 ↗
  • Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015 Jan;55(1):21-34. doi: 10.1111/head.12482. PubMed 25600719 ↗
  • Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021 Jan;61(1):60-68. doi: 10.1111/head.14024. Epub 2020 Dec 21. PubMed 33349955 ↗
  • Friedman BW, Mulvey L, Esses D, Solorzano C, Paternoster J, Lipton RB, Gallagher EJ. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med. 2011 May;57(5):475-82.e1. doi: 10.1016/j.annemergmed.2010.11.023. Epub 2011 Jan 12. PubMed 21227540 ↗
  • Motov S, Yasavolian M, Likourezos A, Pushkar I, Hossain R, Drapkin J, Cohen V, Filk N, Smith A, Huang F, Rockoff B, Homel P, Fromm C. Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2017 Aug;70(2):177-184. doi: 10.1016/j.annemergmed.2016.10.014. Epub 2016 Dec 16. PubMed 27993418 ↗
  • Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav. 2018 Jun;8(6):e00950. doi: 10.1002/brb3.950. Epub 2018 May 2. PubMed 30106228 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2023 to primary completion in Aug 2026, 37 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Jan 2024 → Jun 2023, primary completion Jun 2024 → Aug 2026 and completion Jun 2024 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 9, 2023
StartActual
Jun 28, 2023was Jan 2024
Primary completionActual
Aug 7, 2026was Jun 2024
CompletionActual
Aug 7, 2026was Jun 2024
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn The project proved not feasible to launch at Health Sciences North.
changed Oct 5, 2026
Start date
Jan 1, 2024→Jun 28, 2023 (actual)
Oct 5, 2026
Primary completion
Jun 30, 2024→Aug 7, 2026 (actual)
Oct 5, 2026
Study completion
Jun 30, 2024→Aug 7, 2026 (actual)
Oct 5, 2026
Enrollment
55 (estimated)→0 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Withdrawn
    Why stopped The project proved not feasible to launch at Health Sciences North.
    Start date Jan 1, 2024→Jun 28, 2023 (now actual)
    Primary completion Jun 30, 2024→Aug 7, 2026 (now actual)
    Study completion Jun 30, 2024→Aug 7, 2026 (now actual)
    Enrollment 55 (estimated)→0 (actual)
    + 5 other changes: index terms, verification date, criteria formatting, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05983354
Lead sponsor
Health Sciences North Research Institute
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Jun 28, 2023
Primary completion
Aug 7, 2026
Completion
Aug 7, 2026
Last update
Oct 5, 2026

Study contacts

Robert Ohle, MBBCh
principal investigator · Health Sciences North Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metoclopramide · Ibuprofen

Start the discussion